DCM
KYMR icon

DAFNA Capital Management’s Kymera Therapeutics KYMR Stock Holding History

DAFNA Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
+27,000
New +$2.32M 0.59% 35

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

DAFNA Capital Management's KYMR Position: Q2 2026 in Review

DAFNA Capital Management opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 27,000 shares worth $3.1M. The stake represents 0.59% of the portfolio and ranks #35 among its holdings.

275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • DAFNA Capital Management held 27,000 shares of Kymera Therapeutics worth $3.1M as of Q2 2026.
  • Kymera Therapeutics was a new DAFNA Capital Management position in Q2 2026.
  • Kymera Therapeutics made up 0.59% of DAFNA Capital Management's portfolio in Q2 2026, its #35 holding.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.